Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

FPF 1070

Drug Profile

FPF 1070

Alternative Names: Cerebrolysin

Latest Information Update: 25 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ebewe Neuro Pharma
  • Developer EVER Neuro Pharma
  • Class Nootropics; Peptides; Tissue extracts
  • Mechanism of Action Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Alzheimer's disease; Stroke
  • Phase II CADASIL
  • Discontinued Brain injuries

Most Recent Events

  • 29 Nov 2023 Phase-II clinical trials in CADASIL in Czech Republic (unspecified route) (NCT05755997) (EudraC2022-002394-29)
  • 28 Jul 2022 Ever Neuro Pharma terminates a phase II IMPULSE trial in Stroke in Austria due to strategic and pandemic reasons (NCT04124367)
  • 25 Jun 2021 Ever Neuro Pharma initiates a phase II IMPULSE trial for Stroke in Austria (NCT04124367)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top